Picture EBD Group Biotech Showcase 2025 San Francisco BTS25 650x100px

Product › Details

LSD1 inhibitor (Lysine Specific Demethylase-1 inhibitor)

	Next higher product group	cancer drug
	Status	2014-04-07 development p2 existent
	Organisation	Roche (Group)
	Organisation 2	Oryzon Genomics S.A. (Madrid Stock Exchange: ORY)
	Group	Oryzon Genomics (Group)

Record changed: 2023-07-10

Picture EBD Group Biotech Showcase 2025 San Francisco BTS25 650x200px

More documents for cancer drug

[1] Orbit Discovery Ltd.. (12/3/24). "Press Release: Orbit Discovery and Evergreen Theragnostics Expand Research Collaboration to Advance Targeted Therapeutics Development". Oxford & Springfield, NJ....
[2] Ipsen S.A.. (12/3/24). "Press Release: Ipsen and Biomunex Announce Exclusive Global Licensing Agreement for First-in-Class MAIT Cell Engager in Immuno-oncology". Paris....
[3] Tubulis GmbH. (12/3/24). "Press Release: Gilead and Tubulis Enter into Exclusive Option and Licence Agreement to Develop ADC Candidate for Select Solid Tumor Target". Foster City, CA & Munich....
[4] Medigene AG. (11/26/24). "Press Release: Medigene AG Announces Refocus of Corporate Strategy and Organizational Realignment". Basel....
[5] Adcendo ApS. (11/25/24). "Press Release: Adcendo ApS Completes Oversubscribed $135 Million Series B Financing to Advance First-in-class ADC Pipeline". Copenhagen....
[6] BioNTech SE. (11/13/24). "Press Release: BioNTech to Acquire Biotheus to Boost Oncology Strategy". Mainz....
[7] Alentis Therapeutics AG. (11/12/24). "Press Release: Alentis Therapeutics Raises $181.4 Million in an Oversubscribed Series D Financing to Advance the Clinical Development of Anti-Claudin-1 ADCs in Solid Tumors". Basel....
[8] Ottimo Pharma Ltd.. (10/28/24). "Press Release: Ottimo Pharma Emerges from Stealth with Backing from Medicxi and Management Team Led by David Epstein to Accelerate Development of a Novel PD1/VEGFR2 Bi-Functional Antibody Planned to Enter the Clinic in 20...
[9] Innate Pharma S.A.. (10/14/24). "Press Release: Innate Pharma Appoints Jonathan Dickinson as New Chief Executive Officer and Chairman of the Executive Board"....
[10] Immatics N.V.. (10/10/24). "Press Release: Immatics Announces Proposed $150 Million Public Offering". Houston, TX & Tübingen....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]